Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 8/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24355412 | 0.87 | GAK (0.56) | PDPK1GAKEGFRKDRENPP1 | |
| SCHEMBL4417599 | 0.83 | GAK (0.53) | PDPK1GAKEGFRKDRENPP1 | |
| SCHEMBL4420286 | 0.83 | GAK (0.53) | PDPK1GAKEGFRKDRENPP1 | |
| SCHEMBL2221126 | 0.82 | KDM1A (0.57) | PDPK1GAKEGFRKDRKDM1A | |
| SCHEMBL29736163 | 0.82 | KDM1A (0.57) | PDPK1GAKEGFRKDRKDM1A | |
| SCHEMBL4747754 | 0.80 | PDPK1 (0.68) | PDPK1KDRFLT1 | |
| SCHEMBL20285420 | 0.78 | KDM1A (0.54) | GAKEGFRKDRKDM1A | |
| SCHEMBL4747109 | 0.77 | PDPK1 (0.70) | PDPK1 | |
| SCHEMBL4741555 | 0.77 | PDPK1 (0.73) | PDPK1 | |
| SCHEMBL4745738 | 0.76 | PDPK1 (0.61) | PDPK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PDPK1 6/4885GAK 26/4885EGFR 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.